Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes

Katsunori Nakamura, Noritaka Ariyoshi, Takafumi Iwatsubo, Yasuhisa Fukunaga, Saburou Higuchi, Kunio Itoh, Noriaki Shimada, Kazuo Nagashima, Tsuyoshi Yokoi, Koujirou Yamamoto, Ryuya Horiuchi, Tetsuya Kamataki

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

To anticipate drug-drug interactions by nicardipine in vivo, cytochrome P450 (CYP) forms responsible for the metabolism of nicardipine and inhibition of CYP-dependent drug metabolism by nicardipine were investigated. Microsomes of human B-lymphoblastoid cells expressing each human CYP form were used for the metabolism of nicardipine. Inhibitory effects of nicardipine on drug metabolism were studied using human liver microsomes. CYP2C8, CYP2D6 and CYP3A4 were identified as major CYP forms for the metabolism of nicardipine in human liver microsomes. Nicardipine strongly inhibited two-pathways of triazolam hydroxylation both catalyzed by CYP3A4. Comparison of three Ca2+ antagonists, nicardipine, nifedipine, and diltiazem revealed that only nicardipine showed such a strong inhibitory potency on the typical CYP2D6-catalyzed drug metabolism. Furthermore, nicardipine inhibited other reactions catalyzed by CYP1A, CYP2A6, CYP2C8, CYP2C9 and CYP2C19 with K i values ranging from 1.1 to 29.4μM. In conclusion, nicardipine was a relatively potent inhibitor of human CYP2D6, CYP3A4 and CYP2C (especially for CYP2C8 and CYP2C19) in vitro, suggesting that drug-drug interactions between nicardipine and other drugs metabolized mainly by these CYP forms appear to occur in vivo.

Original languageEnglish
Pages (from-to)882-885
Number of pages4
JournalBiological and Pharmaceutical Bulletin
Volume28
Issue number5
DOIs
Publication statusPublished - May 2005
Externally publishedYes

Fingerprint

Nicardipine
Liver Microsomes
Cytochrome P-450 Enzyme System
Cytochrome P-450 CYP3A
Cytochrome P-450 CYP2D6
Pharmaceutical Preparations
Drug Interactions
Triazolam
Diltiazem
Hydroxylation
Nifedipine
Microsomes

Keywords

  • Ca blocker
  • Diltiazem
  • Drug-drug interaction
  • Nifedipine

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. / Nakamura, Katsunori; Ariyoshi, Noritaka; Iwatsubo, Takafumi; Fukunaga, Yasuhisa; Higuchi, Saburou; Itoh, Kunio; Shimada, Noriaki; Nagashima, Kazuo; Yokoi, Tsuyoshi; Yamamoto, Koujirou; Horiuchi, Ryuya; Kamataki, Tetsuya.

In: Biological and Pharmaceutical Bulletin, Vol. 28, No. 5, 05.2005, p. 882-885.

Research output: Contribution to journalArticle

Nakamura, K, Ariyoshi, N, Iwatsubo, T, Fukunaga, Y, Higuchi, S, Itoh, K, Shimada, N, Nagashima, K, Yokoi, T, Yamamoto, K, Horiuchi, R & Kamataki, T 2005, 'Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes', Biological and Pharmaceutical Bulletin, vol. 28, no. 5, pp. 882-885. https://doi.org/10.1248/bpb.28.882
Nakamura, Katsunori ; Ariyoshi, Noritaka ; Iwatsubo, Takafumi ; Fukunaga, Yasuhisa ; Higuchi, Saburou ; Itoh, Kunio ; Shimada, Noriaki ; Nagashima, Kazuo ; Yokoi, Tsuyoshi ; Yamamoto, Koujirou ; Horiuchi, Ryuya ; Kamataki, Tetsuya. / Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. In: Biological and Pharmaceutical Bulletin. 2005 ; Vol. 28, No. 5. pp. 882-885.
@article{5149b4b15e7f4b8791463dc3231dd453,
title = "Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes",
abstract = "To anticipate drug-drug interactions by nicardipine in vivo, cytochrome P450 (CYP) forms responsible for the metabolism of nicardipine and inhibition of CYP-dependent drug metabolism by nicardipine were investigated. Microsomes of human B-lymphoblastoid cells expressing each human CYP form were used for the metabolism of nicardipine. Inhibitory effects of nicardipine on drug metabolism were studied using human liver microsomes. CYP2C8, CYP2D6 and CYP3A4 were identified as major CYP forms for the metabolism of nicardipine in human liver microsomes. Nicardipine strongly inhibited two-pathways of triazolam hydroxylation both catalyzed by CYP3A4. Comparison of three Ca2+ antagonists, nicardipine, nifedipine, and diltiazem revealed that only nicardipine showed such a strong inhibitory potency on the typical CYP2D6-catalyzed drug metabolism. Furthermore, nicardipine inhibited other reactions catalyzed by CYP1A, CYP2A6, CYP2C8, CYP2C9 and CYP2C19 with K i values ranging from 1.1 to 29.4μM. In conclusion, nicardipine was a relatively potent inhibitor of human CYP2D6, CYP3A4 and CYP2C (especially for CYP2C8 and CYP2C19) in vitro, suggesting that drug-drug interactions between nicardipine and other drugs metabolized mainly by these CYP forms appear to occur in vivo.",
keywords = "Ca blocker, Diltiazem, Drug-drug interaction, Nifedipine",
author = "Katsunori Nakamura and Noritaka Ariyoshi and Takafumi Iwatsubo and Yasuhisa Fukunaga and Saburou Higuchi and Kunio Itoh and Noriaki Shimada and Kazuo Nagashima and Tsuyoshi Yokoi and Koujirou Yamamoto and Ryuya Horiuchi and Tetsuya Kamataki",
year = "2005",
month = "5",
doi = "10.1248/bpb.28.882",
language = "English",
volume = "28",
pages = "882--885",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "5",

}

TY - JOUR

T1 - Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes

AU - Nakamura, Katsunori

AU - Ariyoshi, Noritaka

AU - Iwatsubo, Takafumi

AU - Fukunaga, Yasuhisa

AU - Higuchi, Saburou

AU - Itoh, Kunio

AU - Shimada, Noriaki

AU - Nagashima, Kazuo

AU - Yokoi, Tsuyoshi

AU - Yamamoto, Koujirou

AU - Horiuchi, Ryuya

AU - Kamataki, Tetsuya

PY - 2005/5

Y1 - 2005/5

N2 - To anticipate drug-drug interactions by nicardipine in vivo, cytochrome P450 (CYP) forms responsible for the metabolism of nicardipine and inhibition of CYP-dependent drug metabolism by nicardipine were investigated. Microsomes of human B-lymphoblastoid cells expressing each human CYP form were used for the metabolism of nicardipine. Inhibitory effects of nicardipine on drug metabolism were studied using human liver microsomes. CYP2C8, CYP2D6 and CYP3A4 were identified as major CYP forms for the metabolism of nicardipine in human liver microsomes. Nicardipine strongly inhibited two-pathways of triazolam hydroxylation both catalyzed by CYP3A4. Comparison of three Ca2+ antagonists, nicardipine, nifedipine, and diltiazem revealed that only nicardipine showed such a strong inhibitory potency on the typical CYP2D6-catalyzed drug metabolism. Furthermore, nicardipine inhibited other reactions catalyzed by CYP1A, CYP2A6, CYP2C8, CYP2C9 and CYP2C19 with K i values ranging from 1.1 to 29.4μM. In conclusion, nicardipine was a relatively potent inhibitor of human CYP2D6, CYP3A4 and CYP2C (especially for CYP2C8 and CYP2C19) in vitro, suggesting that drug-drug interactions between nicardipine and other drugs metabolized mainly by these CYP forms appear to occur in vivo.

AB - To anticipate drug-drug interactions by nicardipine in vivo, cytochrome P450 (CYP) forms responsible for the metabolism of nicardipine and inhibition of CYP-dependent drug metabolism by nicardipine were investigated. Microsomes of human B-lymphoblastoid cells expressing each human CYP form were used for the metabolism of nicardipine. Inhibitory effects of nicardipine on drug metabolism were studied using human liver microsomes. CYP2C8, CYP2D6 and CYP3A4 were identified as major CYP forms for the metabolism of nicardipine in human liver microsomes. Nicardipine strongly inhibited two-pathways of triazolam hydroxylation both catalyzed by CYP3A4. Comparison of three Ca2+ antagonists, nicardipine, nifedipine, and diltiazem revealed that only nicardipine showed such a strong inhibitory potency on the typical CYP2D6-catalyzed drug metabolism. Furthermore, nicardipine inhibited other reactions catalyzed by CYP1A, CYP2A6, CYP2C8, CYP2C9 and CYP2C19 with K i values ranging from 1.1 to 29.4μM. In conclusion, nicardipine was a relatively potent inhibitor of human CYP2D6, CYP3A4 and CYP2C (especially for CYP2C8 and CYP2C19) in vitro, suggesting that drug-drug interactions between nicardipine and other drugs metabolized mainly by these CYP forms appear to occur in vivo.

KW - Ca blocker

KW - Diltiazem

KW - Drug-drug interaction

KW - Nifedipine

UR - http://www.scopus.com/inward/record.url?scp=21144458074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21144458074&partnerID=8YFLogxK

U2 - 10.1248/bpb.28.882

DO - 10.1248/bpb.28.882

M3 - Article

VL - 28

SP - 882

EP - 885

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 5

ER -